Carrasco GH, Rojas GP, Serrano LJA, Sánchez NN, Rojas GC

Language: Spanish
References: 18
Page: 14-18
PDF size: 0. Kb.

ABSTRACT

Objective: The purpose of this study is to report the trousseau’s cases that we have had during twelve years, between 1997 to 2009.
Brakground: Trousseau’s syndrome is defined like the association between venous tromboembolismo and malignancy. Arman Trousseau was the first to describe this association in 1865.
Method: This is a retrospective, descriptive and observational study that include patients with venous thrombosis and cancer.
Results: 99 patients with mean age of 66.9 years were included in this study. 43 were woman and 56 were men. In particular lung cancer was found to be associated with venous thromboembolism. The most common cause of death in these patients was pulmonary embolism. The clinical presentation of these patients was venous thrombosis and migratory thrombosis.
Conclusion: Our experience suggest thet the clinic presentation of Trousseau’s syndrome is venous thromboembolism. Almost, any malignancy can cause venous thromboembolism being the most common cause of death, pulmonary embolism.

REFERENCES

1. Otten HM, Prins MH. Venous Thromboembolism and Occult Malignancy. Thrombosis Research 2001; 102: 187-94.

2. Prandoni P, Falanga A, Piccioli A. Cancer and venous Thromoembolism. Lancet 2005; 6: 401-10.

3. Ihnat D, Mills JL, Hughes JD, Gentile A, Berman S, Wasterband A. Treatment of Patients with Venous Thromoembolism and Malignant Disease: Should Vena Cava filter Replacement be Routine? J Vasc Surg 1998; 28: 800-7.

4. Bloom JW, Doggen CJ, Osanto S, Rosendal FR. Malignancies, Prothrombotic Mutations and the Risk of Venous Thromboembolism. JAMA 2005; 293(3): 715-22.

5. Deitcher SR. Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies. Seminars in Thrombosis and Hemostasis 2003; 29(3): 247-55.

6. Mousa SA, Low Molecular-Weight Heparin in Thrombosis and Cancer. Seminars in Thrombosis and Hemostasis 2004; 30: 25-9.

7. Bauer K. Venous Throemboembolism in Malignancy. J Clin Oncol 2000; 18(17): 3065-7.

8. Lin J, Proctor C, Varma M, Greenfield LJ, Upchurch G, Henke PK. Factors Associated with Recurrent Venous Throemboembolism in Patients with Malignant Disease. J Vasc Surg 2003; 37: 976: 83.

9. Kwaan HC, Parmar S, Wang J. Pathogenesis of Increased Risk of Thrombosis in Cancer. Seminars in Thrombosis and Hemostasis 2003; 29(3): 283-9.

10. Sato T, Tsujino I, Ikeda D, Leko M, Nishimura M. Trousseau’s Syndrome Associated with Tissue Factor Produced by Pulmonary adenocarcinoma. Thorax 2006; 61: 1009-10.

11. Varki A. Trousseau’s Syndrome: Multiple Definitions and Multiple Mechanisms. Blood 2007; 110(6): 1723-9.

12. Behranwala K, Williamson R. Cancer-Associated venous Thrombosis in the Surgical Setting. Annals of Surgery 2009; 249(3): 366-73.

13. De Cicco M. The Prothrombotic State in Cancer: Pathogenic Mechanisms. Critical Review in Hematology and Oncology 2003; 50(3): 187-96.

14. Kakkar A. Low-Molecular-Weight Heparins: Beyond Thrombosis in the Management of the Cancer patient. Seminars in Thrombosis and Hemostasis 2003; 9(1): 13-15.

15. Goad K, Grainick H. Hematologic complications in cancer. Hematol/Oncol Clin North Am 1996; 10(2): 457-72.

16. Mousa SA. Anticoagulans in Thrombosis and Cancer: The Missing Link. Seminars in Thrombosis and Hemostasis 2002; 28(1): 45-52.

17. Pruemer J. Prevalence, Causes, and Impact of Cancer-Associated Thrombosis. Am J Health Syst Pharmacol 2005; 62: 54-6.

18. Carrier M, Le Gal G, Wells P, Fergusson D, Ramsay T, Rodger M. Systematic Review: The trousseau Syndrome Revisted: Should we Screen Extensively for Cancer in Patients with venous Thromboembolism? Annals of Internal Medicine 2008; 149: 323-33.